Jeff Yass’s Iterum Therapeutics ITRM Stock Holding History

Jeff Yass’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,701	Closed	-$7.84K	–	12969
2025 Q3	$7.84K	Buy	+11,701	New	+$9.16K	﹤0.01%	12113
2024 Q3	–	Sell	-38,483	Closed	-$44.6K	–	12490
2024 Q2	$44.6K	Buy	+38,483	New	+$55.7K	﹤0.01%	11460
2024 Q1	–	Sell	-17,533	Closed	-$34.5K	–	12731
2023 Q4	$34.5K	Sell	17,533 -30,123	-63%	-$37.3K	﹤0.01%	11842
2023 Q3	$39.6K	Buy	47,656 +34,506	+262%	+$32.8K	﹤0.01%	11394
2023 Q2	$14.1K	Buy	+13,150	New	+$14.6K	﹤0.01%	11707
2022 Q2	–	Sell	-1,953	Closed	-$10K	–	13402
2022 Q1	$10K	Buy	+1,953	New	+$11.3K	﹤0.01%	12749

Other funds holding ITRM

Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Alchemi Wealth Essex, Connecticut $213M AUM

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GWP

Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return

Jeff Yass's ITRM Position: Q4 2025 in Review

Jeff Yass sold out of Iterum Therapeutics (ITRM) in Q4 2025, closing a stake of 11,701 shares — an estimated $7.84K sold.

Jeff Yass first reported a position in ITRM in Q1 2022 and held it in 6 quarters. The position peaked at $44.6K in Q2 2024. 20 funds tracked by Wall St. Rank hold ITRM as of Q4 2025.

Jeff Yass reported no remaining Iterum Therapeutics position as of Q4 2025 after selling out during the quarter.
Jeff Yass sold 11,701 Iterum Therapeutics shares in Q4 2025, an estimated $7.84K.
Jeff Yass first reported a position in Iterum Therapeutics in Q1 2022 and held it in 6 quarters.
Jeff Yass's Iterum Therapeutics position peaked at $44.6K in Q2 2024.
20 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.